Longitudinal Bladder Cancer Study for Tumour Recurrence

RecruitingOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

May 30, 2026

Study Completion Date

August 31, 2026

Conditions
Urothelial Bladder Cancer
Interventions
DIAGNOSTIC_TEST

CxBladder Monitor/Monitor+

CxBladder Monitor/Monitor+ is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.

Trial Locations (7)

3165

RECRUITING

Monash Health - Moorabbin Hospital, Clayton

29401

RECRUITING

Ralph H. Johnson VA Health Care System, Charleston

33125

RECRUITING

Miami VA Healthcare System, Miami

33612

RECRUITING

James A. Haley Veteran's Hospital, Tampa

75390

RECRUITING

UT Southwestern Medical Center, Dallas

98195

RECRUITING

University of Washington School of Medicine, Seattle

05009

RECRUITING

White River Junction Veterans Affair Medical Center, White River Junction

Sponsors
All Listed Sponsors
lead

Pacific Edge Limited

INDUSTRY

NCT05080998 - Longitudinal Bladder Cancer Study for Tumour Recurrence | Biotech Hunter | Biotech Hunter